Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, June 28, 2026

Remote Ischemic Postconditioning in Endovascular Thrombectomy for Stroke: The EnTRIPS Randomized Clinical Trial

 

Is your doctor and stroke hospital so FUCKING INCOMPETENT THEY DIDN'T CREATE AND INSTALL A PROTOCOL ON THIS YEARS AGO?

Do you prefer your doctor and hospital incompetence being NOT KNOWING. Or NOT DOING?


  • remote ischemic postconditioning (5 posts to March 2021)

    • And much earlier, this might be 

    Remote Ischemic Postconditioning in Endovascular Thrombectomy for Stroke: The EnTRIPS Randomized Clinical Trial


    Yawen Cheng, MD https://orcid.org/0000-0001-9841-9800, Wanying Chen, MD https://orcid.org/0000-0003-0812-1408, 
    Mingze Chang, MD https://orcid.org/0000-0001-8475-6603, Xiangning Han, MS https://orcid.org/0000-0003-2282-6279, 
    Jia Yu, MD https://orcid.org/0009-0001-9199-2046, Meng Wei, MD https://orcid.org/0009-0004-5765-7414, 
    Yi Qi, MS, … Show All … , and Guogang Luo, MD https://orcid.org/0000-0003-3991-8962 lguogang@163.comAuthor Info & Affiliations
    Stroke
    New online
    https://doi.org/10.1161/STROKEAHA.126.054857

     

    Abstract

    BACKGROUND:

    Although the neuroprotective potential of remote ischemic postconditioning (RIPC) has been reported, the efficacy and safety of ultra-early RIPC administered after endovascular treatment (EVT) in patients with acute ischemic stroke remain unclear. This study evaluated the efficacy and safety of ultra-early RIPC in patients with acute ischemic stroke undergoing EVT.

    METHODS:

    The EnTRIPS trial (Endovascular Treatment Combined with Remote Ischemic Postconditioning in Patients with Acute Ischemic Stroke) was a multicenter, randomized, controlled, outcome assessor-blinded, prospective clinical trial. The trial was conducted at 8 hospitals in China between April 12, 2021, and March 26, 2025. Eligible patients were adults with acute ischemic stroke due to large vessel occlusion who presented within 24 hours of symptom onset, underwent EVT, and achieved successful recanalization. A total of 270 eligible patients were randomized within 6 hours after EVT to receive either RIPC plus guideline-based therapy (n=135) or guideline-based therapy alone (n=135). RIPC was administered for 7 days using pneumatic devices consisting of 5 cycles of bilateral upper-arm cuff inflation (5 minutes at 180 mm Hg) followed by deflation (3 minutes). The primary outcome was functional independence at 90 days, defined as a modified Rankin Scale score of 0 to 2 (range, 0 [no symptoms] to 6 [death]). Safety outcomes included the incidence of RIPC-related adverse events within 7 days.

    RESULTS:

    Among 270 randomized patients, a total of 268 (99.3%) participants completed the trial, including 133 in the RIPC group and 135 in the control group (mean [SD] age, 65.5 [16.8] years; 171 [63.8%] men). At 90 days, functional independence was achieved in 81 (60.9%) patients in the RIPC group and 78 (57.8%) patients in the control group (adjusted risk ratio, 1.07 [95% CI, 0.89–1.30]; P=0.46). RIPC-related adverse events occurred in 10 of 133 (7.5%) patients, and no intervention-related adverse events occurred in the control group.

    CONCLUSIONS:

    Ultra-early RIPC is safe for patients with acute ischemic stroke treated with EVT, but it does not significantly improve the 90-day functional outcomes.

    REGISTRATION:

    URL: https://www.clinicaltrials.gov; Unique identifier: NCT04581759.

    Graphical Abstract



    Get full access to this article

    Posted by at
    Labels: , , , , , , ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)